Predictive Value of Plasma Atherogenic Index for Microalbuminuria in Newly Diagnosed Patients with Type 2 Diabetes Mellitus

References

• Microvascular Complications Group of Diabetes Branch of Chinese Medical Association. Guidelines for the prevention and treatment of diabetic nephropathy in China (2021 edition). Chin J Diabetes. 2021;13(08):762–784.
   Google Scholar
• Gabriel R, Boukichou AN, Acosta T, et al. Early prevention of diabetes microvascular complications in people with hyperglycaemia in Europe. ePREDICE randomized trial. Study protocol, recruitment and selected baseline data. PLoS One. 2020;15(4):e231196. doi:10.1371/journal.pone.0231196
   PubMed Web of Science ®Google Scholar
• Dobiasova M, Raslova K, Rauchova H, et al. Atherogenic lipoprotein profile in families with and without history of early myocardial infarction. Physiol Res. 2001;50(1):1–8.
   PubMed Web of Science ®Google Scholar
• Cai G, Shi G, Xue S, et al. The atherogenic index of plasma is a strong and independent predictor for coronary artery disease in the Chinese Han population. Medicine. 2017;96(37):e8058. doi:10.1097/MD.0000000000008058
   PubMed Web of Science ®Google Scholar
• Kim JJ, Yoon J, Lee YJ, et al. Predictive value of the atherogenic index of plasma (aip) for the risk of incident ischemic heart disease among non-diabetic Koreans. Nutrients. 2021;13(9):3231. doi:10.3390/nu13093231
   Web of Science ®Google Scholar
• Tan MH, Johns D, Glazer NB. Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes. Clin Chem. 2004;50(7):1184–1188. doi:10.1373/clinchem.2004.031757
   PubMed Web of Science ®Google Scholar
• Fu L, Zhou Y, Sun J, et al. Atherogenic index of plasma is associated with major adverse cardiovascular events in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2021;20(1):201. doi:10.1186/s12933-021-01393-5
   PubMed Web of Science ®Google Scholar
• Diabetes Branch of Chinese Medical Association. Guidelines for the prevention and treatment of type 2 diabetes in China (2020 Edition) . Int J Endocrinol Metab. 2021;41(5):482–548.
   Google Scholar
• Santoro D, Torreggiani M, Pellicano V, et al. Kidney biopsy in type 2 diabetic patients: critical reflections on present indications and diagnostic alternatives. Int J Mol Sci. 2021;22(11):5425. doi:10.3390/ijms22115425
   PubMed Web of Science ®Google Scholar
• Gembillo G, Ingrasciotta Y, Crisafulli S, et al. Kidney disease in diabetic patients: from pathophysiology to pharmacological aspects with a focus on therapeutic inertia. Int J Mol Sci. 2021;22(9):4824. doi:10.3390/ijms22094824
   PubMed Web of Science ®Google Scholar
• Opazo-Rios L, Mas S, Marin-Royo G, et al. Lipotoxicity and diabetic nephropathy: novel mechanistic insights and therapeutic opportunities. Int J Mol Sci. 2020;21(7):2632. doi:10.3390/ijms21072632
   PubMed Web of Science ®Google Scholar
• Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular StudY. Circulation. 1997;95(1):69–75. doi:10.1161/01.cir.95.1.69
   PubMed Web of Science ®Google Scholar
• Shiying L, Zheng L, Jinxia Z, et al. The relationship between oxidized low density lipoprotein, monocyte chemoattractant protein 1 and carotid atherosclerosis after cerebral infarction. Chin J Atheroscler. 2016;24(05):495–498.
   Google Scholar
• Zhu XW, Deng FY, Lei SF. Meta-analysis of Atherogenic Index of Plasma and other lipid parameters in relation to risk of type 2 diabetes mellitus. Prim Care Diabetes. 2015;9(1):60–67. doi:10.1016/j.pcd.2014.03.007
   PubMed Web of Science ®Google Scholar
• Ma X, Sun Y, Cheng Y, et al. Prognostic impact of the atherogenic index of plasma in type 2 diabetes mellitus patients with acute coronary syndrome undergoing percutaneous coronary intervention. Lipids Health Dis. 2020;19(1):240. doi:10.1186/s12944-020-01418-0
   PubMed Web of Science ®Google Scholar
• Zhou K, Qin Z, Tian J, et al. The atherogenic index of plasma: a powerful and reliable predictor for coronary artery disease in patients with type 2 diabetes. Angiology. 2021;72(10):934–941. doi:10.1177/00033197211012129
   PubMed Web of Science ®Google Scholar
• Si Y, Fan W, Han C, et al. Atherogenic Index of plasma, triglyceride-glucose index and monocyte-to-lymphocyte ratio for predicting subclinical coronary artery disease. Am J Med Sci. 2021;362(3):285–290. doi:10.1016/j.amjms.2021.05.001
   Web of Science ®Google Scholar
• McNamara JR, Jenner JL, Li Z, et al. Change in LDL particle size is associated with change in plasma triglyceride concentration. Arterioscler Thromb. 1992;12(11):1284–1290. doi:10.1161/01.atv.12.11.1284
   Web of Science ®Google Scholar
• Herman-Edelstein M, Scherzer P, Tobar A, et al. Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy. J Lipid Res. 2014;55(3):561–572. doi:10.1194/jlr.P040501
   PubMed Web of Science ®Google Scholar
• Chang Y, Ryu S, Choi Y, et al. Metabolically healthy obesity and development of chronic kidney disease: a cohort study. Ann Intern Med. 2016;164(5):305–312. doi:10.7326/M15-1323
   PubMed Web of Science ®Google Scholar
• Smajic J, Hasic S, Rasic S. High-density lipoprotein cholesterol, apolipoprotein E and atherogenic index of plasma are associated with risk of chronic kidney disease. Med Glas. 2018;15(2):115–121. doi:10.17392/962-18
   Google Scholar
• Akbas EM, Timuroglu A, Ozcicek A, et al. Association of uric acid, atherogenic index of plasma and albuminuria in diabetes mellitus. Int J Clin Exp Med. 2014;7(12):5737–5743.
   PubMed Web of Science ®Google Scholar
• Schaeffner ES, Kurth T, Curhan GC, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol. 2003;14(8):2084–2091. doi:10.1681/ASN.V1482084
   PubMed Web of Science ®Google Scholar
• Bobulescu IA. Renal lipid metabolism and lipotoxicity. Curr Opin Nephrol Hypertens. 2010;19(4):393–402. doi:10.1097/MNH.0b013e32833aa4ac
   PubMed Web of Science ®Google Scholar
• Thongnak L, Pongchaidecha A, Lungkaphin A. Renal lipid metabolism and lipotoxicity in diabetes. Am J Med Sci. 2020;359(2):84–99. doi:10.1016/j.amjms.2019.11.004
   PubMed Web of Science ®Google Scholar
• Hung CC, Tsai JC, Kuo HT, et al. Dyslipoproteinemia and impairment of renal function in diabetic kidney disease: an analysis of animal studies, observational studies, and clinical trials. Rev Diabet Stud. 2013;10(2–3):110–120. doi:10.1900/RDS.2013.10.110
   PubMedGoogle Scholar
• Yazici D, Sezer H. insulin resistance, obesity and lipotoxicity. Adv Exp Med Biol. 2017;960:277–304. doi:10.1007/978-3-319-48382-5_12
   PubMed Web of Science ®Google Scholar
• Ahmed B, Sultana R, Greene MW. Adipose tissue and insulin resistance in obese. Biomed Pharmacother. 2021;137:111315. doi:10.1016/j.biopha.2021.111315
   PubMed Web of Science ®Google Scholar